A Phase 1b Study to Evaluate the Safety Tolerability and Preliminary Efficacy of ATP150/ATP152 VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Ductal Adenocarcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. No evidence of disease progression or recurrence at any time prior to the first study treatment.
    2. Resolution of all toxicities and any toxic effect(s) of the most recent prior therapy (if applicable) to Grade 1 or less (except alopecia). Patients with = Grade 2 neuropathy and = Grade 2 fatigue may however be enrolled.
    3. Adequate renal, hepatic, and hematologic functions as defined by laboratory parameters = 7 days before study treatment initiation.

You may not be eligible for this study if the following are true:

    1. History of other malignancy =3 years from initiation of study treatment except for: A. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of any site, which were treated with local resection only B. Early stage cancer (e.g., prostate or breast cancer) treated with curative-intent (local therapy only) without evidence of remission for =2 years .
    2. Prior chemotherapy or targeted small molecule therapy within 14 (locally advanced/metastatic PDAC) or 28 (resected PDAC) days from initiation of study treatment. Patients must have recovered to = CTCAE Grade 1 or baseline, except for alopecia of any grade and Grade = 2 peripheral neuropathy.
    3. Prior radiotherapy within 14 (advanced/metastatic PDAC) or 28 (resected PDAC) days from initiation of study treatment. Patients must have recovered from all radiation-related toxicities and not have had radiation pneumonitis.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.